🔴 Lantern Pharma is trading 5.69% down today — no clear company-specific catalyst identified

Lantern Pharma is trading 5.69% down at $1.91 after no clear company-specific catalyst was identified for September 2, 2026.

• Recent coverage centers on the August 14, 2026 second-quarter results and earlier financing, rather than a new announcement.
• The decline is occurring despite biotechnology-sector strength and broader U.S. equity gains.
• The immediate reason remains unconfirmed, and confidence is low because available reporting does not establish a direct catalyst.